Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Objectives:To assess frequency and characteristics oflate responders(>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP).Methods:This is a multicenter (n=16), prospective, real-life study, considering all consecutive adults with high frequency or chronic migraine treated with anti-CGRP mAbs for>24 weeks. We definedresponderspatients with a>50% reduction from baseline in monthly migraine/headache days at weeks 9-12, andlate respondersthose achieving a>50% reduction only afterwards.Results:771 people with migraine completed>24 weeks of anti-CGRP mAbs treatment.Respondersat 12 weeks were 65.6% (506/771) of the patients, while non-responders were 34.4% (265/771). 146 out of the 265 non-responders (55.1%) at 12 weeks responded afterward (late responders): they differed fromrespondersfor higher BMI (+0.78, 95%CI [0.10;1.45]; p=0.024), more frequent treatment failures (+0.52, 95%CI [0.09;0.95]; p=0.017) and psychiatric comorbidities (+10.1%, 95%CI [0.1;0.20]; p=0.041), and less common unilateral pain, alone (-10,9%, 95%CI [-20.5;-1.2]; p=0.025) or in combination with unilateral cranial autonomic symptoms (-12.3%, 95%CI [-20.2;-3.9]; p=0.006) or allodynia (-10.7, 95%CI [-18.2;-3.2]; p=0.01) .Discussion:Half of non-responders to anti-CGRP mAbs at 12 weeks are indeedlate responders. Efficacy of anti-CGRP mAbs should be assessed at 24 weeks while treatment duration should be extended beyond 12 months.
Objectives:To assess frequency and characteristics oflate responders(>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP).Methods:This is a multicenter (n=16), prospective, real-life study, considering all consecutive adults with high frequency or chronic migraine treated with anti-CGRP mAbs for>24 weeks. We definedresponderspatients with a>50% reduction from baseline in monthly migraine/headache days at weeks 9-12, andlate respondersthose achieving a>50% reduction only afterwards.Results:771 people with migraine completed>24 weeks of anti-CGRP mAbs treatment.Respondersat 12 weeks were 65.6% (506/771) of the patients, while non-responders were 34.4% (265/771). 146 out of the 265 non-responders (55.1%) at 12 weeks responded afterward (late responders): they differed fromrespondersfor higher BMI (+0.78, 95%CI [0.10;1.45]; p=0.024), more frequent treatment failures (+0.52, 95%CI [0.09;0.95]; p=0.017) and psychiatric comorbidities (+10.1%, 95%CI [0.1;0.20]; p=0.041), and less common unilateral pain, alone (-10,9%, 95%CI [-20.5;-1.2]; p=0.025) or in combination with unilateral cranial autonomic symptoms (-12.3%, 95%CI [-20.2;-3.9]; p=0.006) or allodynia (-10.7, 95%CI [-18.2;-3.2]; p=0.01) .Discussion:Half of non-responders to anti-CGRP mAbs at 12 weeks are indeedlate responders. Efficacy of anti-CGRP mAbs should be assessed at 24 weeks while treatment duration should be extended beyond 12 months.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.